Table 2 summarizes the principal clinical and pathological characteristics of melanoma patients enrolled in this study. Patients ranged in age from 49 to 74 years, with a mean age of 57.6 years. All patients showed a partial response (PR) to therapy, with a range of TTF (time-to-treatment-failure) from 147 to 362 days. As reported in Figure 7, in all the five melanoma patients, CD147/basigin and MMP-2 plasma levels at disease progression (TP) were significantly higher than those measured at the time of enrolment (p = 0.015 and p = 0.032, respectively). This evidence concerns the gene MMP2 and melanoma.